Logo image of IRD

OPUS GENETICS INC (IRD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IRD - US67577R1023 - Common Stock

2.36 USD
-0.08 (-3.28%)
Last: 12/12/2025, 8:00:02 PM
2.3589 USD
0 (-0.05%)
After Hours: 12/12/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, IRD scores 2 out of 10 in our fundamental rating. IRD was compared to 531 industry peers in the Biotechnology industry. IRD may be in some trouble as it scores bad on both profitability and health. IRD is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IRD had negative earnings in the past year.
In the past year IRD has reported a negative cash flow from operations.
In the past 5 years IRD reported 4 times negative net income.
In the past 5 years IRD reported 4 times negative operating cash flow.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -188.81%, IRD is doing worse than 89.08% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1143.00%, IRD is doing worse than 81.73% of the companies in the same industry.
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

IRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

2

2. Health

2.1 Basic Checks

IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IRD has more shares outstanding
IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -5.84, we must say that IRD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of IRD (-5.84) is worse than 65.54% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that IRD is not too dependend on debt financing.
IRD's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. IRD is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -5.84
ROIC/WACCN/A
WACC8.78%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.23 indicates that IRD should not have too much problems paying its short term obligations.
IRD has a worse Current ratio (1.23) than 85.50% of its industry peers.
IRD has a Quick Ratio of 1.23. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
IRD has a Quick ratio of 1.23. This is amonst the worse of the industry: IRD underperforms 84.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

IRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.85%, which is quite impressive.
The Revenue has grown by 74.60% in the past year. This is a very strong growth!
IRD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 165.10% yearly.
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%

3.2 Future

The Earnings Per Share is expected to grow by 16.21% on average over the next years. This is quite good.
The Revenue is expected to grow by 40.76% on average over the next years. This is a very strong growth
EPS Next Y34.94%
EPS Next 2Y28.38%
EPS Next 3Y17.04%
EPS Next 5Y16.21%
Revenue Next Year49.68%
Revenue Next 2Y43.1%
Revenue Next 3Y34.39%
Revenue Next 5Y40.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IRD's earnings are expected to grow with 17.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.38%
EPS Next 3Y17.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OPUS GENETICS INC

NASDAQ:IRD (12/12/2025, 8:00:02 PM)

After market: 2.3589 0 (-0.05%)

2.36

-0.08 (-3.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners21.28%
Inst Owner ChangeN/A
Ins Owners6.33%
Ins Owner Change7.08%
Market Cap162.75M
Revenue(TTM)14.63M
Net Income(TTM)-68.20M
Analysts81.67
Price Target7.82 (231.36%)
Short Float %0.76%
Short Ratio0.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.18%
Min EPS beat(2)-90.4%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)-7.07%
Min EPS beat(4)-90.4%
Max EPS beat(4)42.04%
EPS beat(8)3
Avg EPS beat(8)-59.5%
EPS beat(12)5
Avg EPS beat(12)-24%
EPS beat(16)8
Avg EPS beat(16)-16.12%
Revenue beat(2)0
Avg Revenue beat(2)-15.16%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-0.87%
Revenue beat(4)2
Avg Revenue beat(4)12.9%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)42.31%
Revenue beat(8)3
Avg Revenue beat(8)-8.15%
Revenue beat(12)6
Avg Revenue beat(12)22.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.75%
PT rev (3m)-4.17%
EPS NQ rev (1m)-6.57%
EPS NQ rev (3m)-3.08%
EPS NY rev (1m)-26.85%
EPS NY rev (3m)-8.46%
Revenue NQ rev (1m)-1.65%
Revenue NQ rev (3m)-10.8%
Revenue NY rev (1m)-2.72%
Revenue NY rev (3m)-7.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.12
P/FCF N/A
P/OCF N/A
P/B 27.27
P/tB 27.27
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.21
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -5.84
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y34.94%
EPS Next 2Y28.38%
EPS Next 3Y17.04%
EPS Next 5Y16.21%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
Revenue Next Year49.68%
Revenue Next 2Y43.1%
Revenue Next 3Y34.39%
Revenue Next 5Y40.76%
EBIT growth 1Y-25.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-242.06%
OCF growth 3YN/A
OCF growth 5YN/A

OPUS GENETICS INC / IRD FAQ

Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRD.


What is the valuation status of OPUS GENETICS INC (IRD) stock?

ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.


Can you provide the profitability details for OPUS GENETICS INC?

OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.


Can you provide the financial health for IRD stock?

The financial health rating of OPUS GENETICS INC (IRD) is 2 / 10.